Screener
Castle Biosciences CSTL EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
FAQ
- What is Castle Biosciences's EBITDA?
- Castle Biosciences (CSTL) reported EBITDA of -$14.48M in Q1 2026.
- How has Castle Biosciences's EBITDA changed year-over-year?
- Castle Biosciences's EBITDA decreased by 888.6% year-over-year, from $1.84M to -$14.48M.
- What is the long-term trend for Castle Biosciences's EBITDA?
- Over 4 years (2021 to 2025), Castle Biosciences's EBITDA has grown at a -51.4% compound annual growth rate (CAGR), from -$36.67M to -$2.04M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Castle Biosciences's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude